Overview
- Several firms including Faruqi & Faruqi, Hagens Berman and The Gross Law Firm are actively soliciting investors to move for lead‑plaintiff appointment before the August 4, 2026 court deadline.
- The lawsuits allege GRAIL and certain executives misled investors about the NHS‑Galleri trial by overstating the sufficiency of a three‑year follow‑up and withholding detailed topline and underlying data.
- GRAIL disclosed on February 19, 2026 that the trial did not meet its primary endpoint of a statistically significant reduction in late‑stage cancers, and GRAL shares fell about 50.55% the next trading day.
- The lead plaintiff typically directs litigation strategy including discovery requests for the trial’s raw data, and plaintiff firms are also encouraging whistleblowers to come forward and consider the SEC whistleblower program.
- Investors who bought GRAL between May 13, 2025 and February 19, 2026 are the putative class and may seek lead status or remain class members while the chosen lead plaintiff will influence whether the case secures broad discovery and potential recovery.